Does the industry no longer need medical representatives?


Release time:

2020-06-19

With the landing of the second batch of national mining, the topic of whether the industry still needs medical representatives has begun to increase on the Internet. Today, Dami saw an interesting statement from the Japanese industry.

 

As we all know, Japan's health policy and market environment in recent years are somewhat similar to those in our country. Recently, Japan has fallen into a common situation because of the epidemic. In addition, at this time of year, the industry will release statistics on the number of medical representatives.

 

Therefore, the medical representatives of small partners are also discussing this topic.

 

First of all, as mature drugs are affected by medical and health policies and medical insurance payments, it is inevitable that the number of medical representatives will decrease. This is the same in many countries. However, this industry can never be without medical representatives.

 

Where did the argument that the industry does not need medical representatives come from? Today, a Japanese partner listed the following four categories of people:

 

The original representative who has been a medical representative but withdrew for various reasons;

 

Still working as a medical representative, but not working well;

 

Envy of medical representatives who are well paid, or outsiders who have no chance to be representatives;

 

Media people who attract attention and create panic in order to traffic.

 

Haha, compare these with our side, is there anything similar?

 

You know, a lot of medical information on the Internet is written by outsiders, or only from a single location to see the industry prospects, the vision is very limited, although this information for senior medical practitioners, do not take it seriously, but for some newcomers who have recently entered the industry, it is easy to cause panic, from some message feedback can indeed be seen.

 

In fact, another common argument is that IT technology is developing very fast and there is no need for representatives to transmit information in the future. This is also impossible. In the past two years, some people said that AI can diagnose, prescribe and even perform surgery without doctors in the future. This logic can also be put on pharmacists. However, it is impossible to think about it a little bit. From ancient times to the present, technology has been a tool, people have to use it.

 

From the cloud office under the epidemic in the past few months, we already know that without solid work offline, online communication and visits are just taken for granted.

 

However, online visits to these new environments are indeed needed in the future. Perhaps what the industry does not need is the medical representatives of the old era, and there is still a strong demand for medical representatives with new capabilities.

 

Is there any change in the current domestic medical practitioners? Not to mention the situation of medical natural persons acting as agents for the time being, strictly speaking, they are not medical representatives. As far as the medical representative employees officially employed by the enterprise are concerned, there are still few people leaving the industry at present. The so-called illusion of "large number of personnel loss" is mostly due to job fluctuations caused by the adjustment of the enterprise's product mix and future drug pipelines under the changing market environment. It is true that job changes and job changes are frequent.

 

For innovative drugs, cutting off the information transmission of pharmaceutical representatives is tantamount to cutting off the lifeline of pharmaceutical companies. We can see that the promotion of many new drugs in the epidemic is at a standstill.

 

Without a pharmaceutical representative, how can we quickly advance the accumulation of clinical experience with innovative drugs and how can we quickly transmit clinical trial data? In today's rapid development of individualized innovative therapies such as gene therapy and cell therapy, there is a lack of data and doctors are simply afraid to use such newly marketed drugs.

 

However, with the advancement of volume procurement, it is inevitable that the number of representative positions responsible for mature drugs will decrease, which will also increase the loss in the next two years. Moreover, enterprises will consider the labor cost and the provision of high-paid old representative positions with mismatched values. Enterprises will transfer to young people with low salaries and easy to cultivate new abilities. Just like Japan, medical representatives have been slowly decreasing these years, in the past two years, it has intensified, with a cumulative decrease of more than 5,000. Most of the lost representatives are in their 40 s and 50 s who left their positions in the form of early retirement.

 

So, in the past of the epidemic, it is inevitable that companies will reconsider the functions and size of their pharmaceutical representatives, reassess the capabilities of their current team of pharmaceutical representatives, and redesign their training and assessment systems.

 

What everyone needs to consider most is, when the number of representatives in this industry decreases, will it be you who will stay?